DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy

Por Liu, Wei, Deng, Lisheng, Song, Yongcheng, Redell, Michele
Publicado em 2014

Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children’s Oncology Group report

Por Long, Xin, Gerbing, Robert B., Alonzo, Todd A., Redell, Michele S.
Publicado no Oncotarget (2017)

Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia

Por Long, Xin, Yu, Yang, Perlaky, Laszlo, Man, Tsz-Kwong, Redell, Michele S.
Publicado no Br J Haematol (2015)

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance

Por Stevens, Alexandra M., Miller, Jennifer M., Munoz, Jaime O., Gaikwad, Amos S., Redell, Michele S.
Publicado no Blood Adv (2017)

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor

Por Redell, Michele S., Ruiz, Marcos J., Alonzo, Todd A., Gerbing, Robert B., Tweardy, David J.
Publicado em 2011

Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L

Por Deng, Lisheng, Zhang, Li, Yao, Yuan, Wang, Cong, Redell, Michele S., Dong, Shuo, Song, Yongcheng
Publicado em 2013

Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

Por Stevens, Alexandra M., Ruiz, Marcos J., Gerbing, Robert B., Alonzo, Todd A., Gamis, Alan S., Redell, Michele S.
Publicado no Haematologica (2015)

Adoptive immunotherapy for AML with CD123-engager T cells

Por Bonifant, Challice, Torres, David, Joseph, Nicholos, Barth, Carolyn Arber, Velasquez, Mireya, Song, Xiao-Tong, Redell, Michele, Gottschalk, Stephen
Publicado no J Immunother Cancer (2015)

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report

Por Redell, Michele S., Ruiz, Marcos J., Gerbing, Robert B., Alonzo, Todd A., Lange, Beverly J., Tweardy, David J., Meshinchi, Soheil
Publicado em 2013

Assessing the intracellular fate of rhodium(II) complexes

Por Minus, Matthew B., Kang, Marci K., Knudsen, Sarah E., Liu, Wei, Krueger, Michael J., Smith, Morgen L., Redell, Michele S., Ball, Zachary T.
Publicado no Chem Commun (Camb) (2016)

Drug Targeting of NR4A Nuclear Receptors for Treatment of Acute Myeloid Leukemia

Por Boudreaux, Seth P., Duren, Ryan P., Call, Steven G., Nguyen, Loc, Freire, Pablo R, Narayanan, Padmini, Redell, Michele S., Conneely, Orla M.
Publicado no Leukemia (2018)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

Por Feng, Zizhen, Yao, Yuan, Zhou, Chao, Chen, Fengju, Wu, Fangrui, Wei, Liping, Liu, Wei, Dong, Shuo, Redell, Michele, Mo, Qianxing, Song, Yongcheng
Publicado no J Hematol Oncol (2016)

Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)

Por Lu, Lianghao, Wen, Yefei, Yao, Yuan, Chen, Fengju, Wang, Guohui, Wu, Fangrui, Wu, Jingyu, Narayanan, Padmini, Redell, Michele, Mo, Qianxing, Song, Yongcheng
Publicado no Theranostics (2018)

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia

Por Bonifant, Challice L, Szoor, Arpad, Torres, David, Joseph, Nicholos, Velasquez, Mireya Paulina, Iwahori, Kota, Gaikwad, Amos, Nguyen, Phuong, Arber, Caroline, Song, Xiao-Tong, Redell, Michele, Gottschalk, Stephen
Publicado no Mol Ther (2016)

Management of Chronic Myeloid Leukemia (CML) in Children and Adolescents: Recommendations from the Children’s Oncology Group CML Working Group

Por Athale, Uma, Hijiya, Nobuko, Patterson, Briana C., Bergsagel, John, Andolina, Jeffrey R., Bittencourt, Henrique, Schultz, Kirk R., Burke, Michael J, Redell, Michele S., Kolb, E. Anders, Johnston, Donna L.
Publicado no Pediatr Blood Cancer (2019)

Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity

Por Minus, Matthew B., Liu, Wei, Vohidov, Farrukh, Kasembeli, Moses M., Long, Xin, Krueger, Michael, Stevens, Alexandra, Kolosov, Mikhail I., Tweardy, David J., Sison, Edward Allen R., Redell, Michele S., Ball, Zachary T.
Publicado no Angew Chem Int Ed Engl (2015)

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia

Por Ataca Atilla, Pinar, McKenna, Mary K, Tashiro, Haruko, Srinivasan, Madhuwanti, Mo, Feiyan, Watanabe, Norihiro, Simons, Brian Wesley, McLean Stevens, Alexandra, Redell, Michele S, Heslop, Helen E, Mamonkin, Maksim, Brenner, Malcolm K, Atilla, Erden
Publicado no J Immunother Cancer (2020)

Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic–inorganic inhibitors

Por Minus, Matthew B., Wang, Haopei, Munoz, Jaime O., Stevens, Alexandra M., Mangubat-Medina, Alicia E., Krueger, Michael J., Liu, Wei, Kasembeli, Moses M., Cooper, Julian C., Kolosov, Mikhail I., Tweardy, David J., Redell, Michele S., Ball, Zachary T.
Publicado no Org Biomol Chem (2020)

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation

Por Stevens, Alexandra M., Xiang, Michael, Heppler, Lisa N., Tošić, Isidora, Jiang, Kevin, Munoz, Jaime O., Gaikwad, Amos S., Horton, Terzah M., Long, Xin, Narayanan, Padmini, Seashore, Elizabeth L., Terrell, Maci C., Rashid, Raushan, Krueger, Michael J., Mangubat-Medina, Alicia E., Ball, Zachary T., Sumazin, Pavel, Walker, Sarah R., Hamada, Yoshimasa, Oyadomari, Seiichi, Redell, Michele S., Frank, David A.
Publicado no Blood Adv (2019)